A database of patient clinical data from 19 clinical studies and a patient population of 16390 was examined to assess the effectiveness and safety of pioglitazone when administered alone, with insulin or in combination with other hypoglycemic medications. The primary outcomes of this investigation were nonfatal myocardial infarction, nonfatal stroke, and death from any cause. This evidence concerns the gene INS and myocardial infarction.